NewLink Genetics to Participate in Upcoming Investor Conferences
- Baird Global Healthcare Conference on September 7 at
1:25pm ET in New York City Cantor Fitzgerald Global Healthcare Conference on September 25 at 4:10pm ET in New York City
A live webcast of both conference presentations will be on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events and Presentations."
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod is being evaluated in combination with treatment regimens including PD-1 checkpoint blockade, cancer vaccines, and chemotherapy across multiple indications such as melanoma, prostate cancer, acute myeloid leukemia, and pancreatic cancer. For more information, please visit http://www.newlinkgenetics.com.
Investor Contact:Lisa Miller Director of Investor RelationsNewLink Genetics (515) 598-2555 lmiller@linkp.com Media Contact:Andrew Mastrangelo AVP, Public & Media Relations LaVoieHealthScience 617-374-8800, ext. 108 amastrangelo@lavoiehealthscience.com
News Provided by Acquire Media